Bagheri Morteza, Taghizadeh-Afshari Ali, Abkhiz Saeed, Abdi-Rad Isa, Mohammadi-Fallah Mohammadreza, Alizadeh Mansour, Sadeghzadeh Saeed
Nephrology and Kidney Transplant Research Center, Urmia University of Medical Sciences, Urmia, Iran.
Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran.
Maedica (Bucur). 2017 Dec;12(4):242-245.
Kidney transplantation supports patients with end-stage kidney diseases. Many factors control the allograft function in kidney transplant recipients. Interleukin-17 (IL-17) can be used as a non-invasive diagnostic biomarker of rejection. The aim of this study was to evaluate the expression of IL-17 mRNA in urinary cells of kidney transplant recipients with stable function.
A total of 40 renal transplant recipients who were admitted for surgery and 30 healthy controls were enrolled in the study. From each patient, 30 mL urine samples were collected in 50 mL tubes on days 3 and 5 after renal transplantation; also, 30 mL urine samples were obtained from controls. Quantitative Real-Time PCR (qRT-PCR) technique was used for analysis of IL-17 mRNA level in the tested groups; 2-ÄÄCT method was performed for determining the relative gene expression between tested groups.
The mRNA expression mean ± SE of fold in patients and controls were 3.58±1.61 fold and 2.85±1.37 fold, respectively. The mRNA expression mean of IL-17 (fold) was not statistically different in tested groups (P-value = 0.63).
In kidney transplant recipients, urinary IL-17 expression provides informative data in relation to the allograft function regardless of allograft pathology.
肾移植为终末期肾病患者提供支持。许多因素控制着肾移植受者的移植肾功能。白细胞介素-17（IL-17）可作为排斥反应的一种非侵入性诊断生物标志物。本研究的目的是评估功能稳定的肾移植受者尿细胞中IL-17 mRNA的表达。
本研究共纳入40例接受手术治疗的肾移植受者和30例健康对照者。在肾移植术后第3天和第5天，从每位患者收集30 mL尿液样本于50 mL试管中；同时，从对照者中获取30 mL尿液样本。采用定量实时聚合酶链反应（qRT-PCR）技术分析检测组中IL-17 mRNA水平；采用2-ΔΔCT法测定检测组之间的相对基因表达。
患者组和对照组的mRNA表达倍数均值±标准误分别为3.58±1.61倍和2.85±1.37倍。检测组中IL-17（倍数）的mRNA表达均值无统计学差异（P值 = 0.63）。
在肾移植受者中，无论移植肾病理情况如何，尿IL-17表达均可提供与移植肾功能相关的信息性数据。
